Related references
Note: Only part of the references are listed.Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2
Charles S. Hummel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Learning From Glycosuria
Ele Ferrannini
DIABETES (2011)
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
M. Obermeier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Sunil Nair et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Sumihiro Nomura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment
Hiroyuki Kakinuma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A Single Amino Acid Change Converts the Sugar Sensor SGLT3 into a Sugar Transporter
Laura Bianchi et al.
PLOS ONE (2010)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
Yoshikazu Fujimori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Songping Han et al.
DIABETES (2008)
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
Yoshikazu Fujimori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine
Rym Aouameur et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Na+-D-glucose cotransporter in the kidney of Squalus acanthias:: molecular identification and intrarenal distribution
T Althoff et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2006)
SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose
S Tazawa et al.
LIFE SCIENCES (2005)
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)
LB Zhou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
A glucose sensor hiding in a family of transporters
A Díez-Sampedro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Identification of a novel Na+/myo-inositol cotransporter
MJ Coady et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder
A Palatnik et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Share Paper
